[July 01, 2016]

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2016 - Research and Markets

Research and Markets has announced the addition of the "Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produe first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Overview
3. Therapeutics Development
4. Pipeline Products for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
5. Pipeline Products for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Comparative Analysis
6. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics under Development by Companies
7. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics under Investigation by Universities/Institutes
8. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Companies
13. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Investigation by Universities/Institutes
14. Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development

• AbbVie Inc.
• Alkermes Plc
• APT (News - Alert) Therapeutics, Inc.
• Mabtech Limited
• Philogen S.p.A.

For more information visit http://www.researchandmarkets.com/research/4c7dtg/interleukin_2

View source version on businesswire.com: http://www.businesswire.com/news/home/20160701005263/en/

[ Back To TMCnet.com's Homepage ]